All entries for: Nurix Therapeutics, Inc.

July 9, 2026

Nurix Therapeutics, Inc.

Neutral Outlook

Brisbane, CA
201-500 employees

It is unclear how future regulatory actions to implement the IRA may affect our products and future profitability

Disease Area: Immune Diseases, Multiple, Oncology
Drug Type: Small Molecule
July 9, 2026

Nurix Therapeutics, Inc.

Neutral Outlook

Brisbane, CA
201-500 employees

The current presidential administration has also signaled its intent to pursue additional healthcare reform measures, including those aimed at reducing prescription drug prices, through various means, including presidential executive orders and agency action. These efforts include, among other things, proposals to establish a “most favored nation” drug pricing policy that would tie U.S. drug prices to the prices paid for drugs in other countries. Additionally, on April 2, 2026, President Trump issued a separate proclamation imposing tariffs on certain imported patented pharmaceuticals and pharmaceutical ingredients pursuant to Section 232 of the Trade Expansion Act of 1962 and linking certain tariff relief to “most-favored-nation” pricing commitments and domestic manufacturing initiatives. Although implementation of the tariffs is subject to phased effective dates beginning in July 2026 for certain manufacturers, it remains to be seen how these drug pricing initiatives will affect the broader pharmaceutical industry.

April 8, 2026

Nurix Therapeutics, Inc.

Neutral Outlook

Brisbane, CA
201-500 employees

Most notably, the Inflation Reduction Act (IRA), which was signed into law on August 16, 2022, allows Medicare to: beginning in 2026, establish a “maximum fair price” for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the Centers for Medicare and Medicaid Services (CMS); and, as of 2023, penalize drug companies that raise prices for products covered under Medicare Parts B and D faster than inflation, among other reforms.

Disease Area: Immune Diseases, Oncology
Drug Type: Small Molecule
Scroll to Top